Launch Blue Announces UAccel Cohort
Launch Blue is pleased to announce the fall 2020 UAccel University Technology Commercialization Focused Cohort. Six Kentucky university technologies were selected to participate in the fall 2020 UAccel program. Candidates were selected through a competitive application and interview process. The final selections for the cohort were determined by a selection committee appointed by the organizing partners.
The UAccel program is a Launch Blue focused cohort organized in partnership with the University of Kentucky (UK) Office of Technology Commercialization and Kentucky Commercialization Ventures. The program is designed to offer professional development and an experiential learning opportunity to innovators in higher education interested in learning the best commercialization path for their technology. The goal of the program is to advance the technology toward commercialization, including preparations for Small Business Innovation Research (SBIR) grant applications, creation of a startup, or licensing of the technology.
Our educational video game, Roots of the Ancients, will transport players to prehistoric times to battle monsters, embark on quests, and speak in ancient tongue, while learning about prehistory, archaeology, mythology, and linguistics.
AmDx is an immunoassay blood test for early diabetes-related microvascular dysfunction that will identify individuals with rapidly progressing micro-vascular disease and would prompt physicians to initiate a proactive, preventative medical treatment.
Malaria is a mosquito-borne infectious disease that remains a leading cause of morbidity and mortality worldwide. Our work focuses on the clinical development of SJ733, a new medicine for the treatment and prevention of malaria.
Affordable and reliable kits for determining water quality are needed by communities and households around the world for preventing waterborne diseases.
Our technology is uniquely positioned to significantly decrease pre-clinical therapeutic study time and cost to ultimately shorten the timeline for veterinary drug approval.
A sensitive and reliable means to measure the amounts of normal and mutant CLN3 proteins in Juvenile Batten disease.
The Fall 2020 UAccel program will begin on September 11th and will conclude on December 4th.